Moderna (MRNA) – Research Analysts’ Recent Ratings Updates

Moderna (NASDAQ: MRNA) recently received a number of ratings updates from brokerages and research firms:

• 7/8/2026 – Moderna had its price target raised by Morgan Stanley from $33.00 to $39.00. They now have an “equal weight” rating on the stock.
• 7/7/2026 – Moderna had its price target raised by Royal Bank Of Canada from $38.00 to $45.00. They now have a “sector perform” rating on the stock.
• 7/7/2026 – Moderna had its price target raised by Bank of America Corporation from $34.00 to $38.00. They now have an “underperform” rating on the stock.
• 6/26/2026 – Moderna had its price target raised by Piper Sandler from $69.00 to $77.00. They now have an “overweight” rating on the stock.
• 6/18/2026 – Moderna had its “hold” rating reaffirmed by Jefferies Financial Group Inc..
• 6/12/2026 – Moderna had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 6/8/2026 – Moderna had its price target raised by Bank of America Corporation from $32.00 to $34.00. They now have an “underperform” rating on the stock.
• 5/26/2026 – Moderna had its “neutral” rating reaffirmed by UBS Group AG.

Insider Buying and Selling at Moderna

In other news, Director Abbas Hussain sold 5,682 shares of Moderna stock in a transaction on Friday, May 1st. The stock was sold at an average price of $46.63, for a total transaction of $264,951.66. Following the transaction, the director owned 12,066 shares in the company, valued at $562,637.58. The trade was a 32.01% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Noubar Afeyan sold 9,263 shares of the business’s stock in a transaction dated Thursday, May 21st. The shares were sold at an average price of $46.84, for a total transaction of $433,878.92. Following the transaction, the director directly owned 3,924 shares in the company, valued at approximately $183,800.16. The trade was a 70.24% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 125,088 shares of company stock valued at $6,193,713. Company insiders own 10.80% of the company’s stock.

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.